Current clinical trials

Patients are invited to participate in clinical trials by the clinical teams involved with their care. There is no obligation to participate. The following are some of the trials currently being conducted locally. More information about current clinical trials can be found at the following websites: Cancer Research UKClinical Research Network Study Portfolio, National Cancer Research Network

  • BREAST

 

IBIS-II DCIS- IBIS-II DCIS: An international multicentre study of Anastrozole vs Tamoxifen in Postmenopausal Women with Ductal Carcinoma in Situ (DCIS

 

IBIS-II Prevention- IBIS-II Prevention: An international multicentre study of Anastrozole vs Placebo in Postmenopausal Women at Increased Risk of Breast Cancer

 

HAMAM- Highly accurate breast cancer diagnosis through integration of biological knowledge, novel imaging modalities, and modelling

 

NCRN155 - ISICA- International Study of Incident Cancer (ISICA) - breast cancer and diabetes

 

POETIC- Trial of Perioperative Endocrine Therapy - Individualising Care

 

SOLD- A randomized phase III study comparing trastuzumab plus docetaxel (HT) followed by 5-FU, epirubicin, and cyclophosphamide (FEC) to the same regimen followed by single-agent trastuzumab as adjuvant treatments for early breast cancer

 

SOLE:Study of Letrozole Extension in post-menopausal women with breast cancer. A phase III trial evaluating the role of continuous letrozole versus intermittent letrozole following 4 to 6 years of prior adjuvant endocrine therapy for post-menopausal women with hormone-receptor positive, node positive early stage breast cancer

 

TARGIT- An international RCT to compare targeted intra-operative radiotherapy with conventional post-operative radiotherapy after conservative breast surgery for women with early stage breast cancer

 

SUPREMO- Selective use of postmastectomy radiotherapy after mastectomy

 

TNT- Triple Negative Breast Cancer Trial: A randomised phase III trial of carboplatin compared to docetaxel for patients with metastatic or recurrent locally advanced ER-, PR- and HER2- or known BRCA1 or BRCA2 mutation associated breast cancer

 National Cancer Research Network current breast cancer clinical trials portfolio maps

Epidemiology, prevention, screening 

Diagnosis and imaging 

Neo adjuvant, peri-operative, surgery

Adjuvant

Metastatic A, Metastatic B

Supportive care, late effects, end of life care

Translational

 

  • COLORECTAL

 

BeWel Phase 2- BeWEL the impact of a BodyWEight and physicaL activity intervention on adults at risk of developing colorectal adenomas. Phase 2

 

COGS2- Colorectal Cancer Genetic Susceptibility Study 2- a development of a strategy for the delivery of genetic screening and counselling and for targeting cancer prevention modalities.

 

EnROL- Conventional versus laparoscopic surgery for colorectal cancer within an Enhanced Recovery Programme

 

CREW (ColoREctal Wellbeing) cohort- A cohort study to explore recovery of health and well-being following primary treatment of colo-rectal cancer

 

QUASAR 2- Multicentre international study capecitabine +/- bevacizumab as adjuvant treatment of colorectal cancer

 

National Cancer Research Network current colorectal cancer clinical trials

Anus specific treatment

Non-specific treatment

Non-treatment A

Non-treatment B

 

  • LUNG

 

BTOG2 - BTOG2 a phase III randomised trial of gemcitabine plus cisplatin at 80mg/m2 versus gemcitabine plus cisplatin at 50mg/m2 versus gemcitabine plus carboplatin AUC6 in stage IIIB/IV non-small cell lung cancer (NSCLC)

 

MALCS (Mesothelioma and Lung Cancer Study)- A population based case-control study of mesothelioma and lung cancer in relation to occupation among British men and women

 

QUARTZ- A phase III multicentre randomised controlled trial to assess whether optimal supportive care (including dexamethasone) alone is as effective as optimal supportive care (including dexamethasone) and whole brain radiotherapy (WBRT) in the treatment of patients with inoperable brain metastases from non-small cell lung cancer (NSCLC)

 National Cancer Research Network current lung cancer clinical trials

All lung cancer

Non small cell

Small cell

Mesothelioma

 

  • HAEMATOLOGY

 

AML 16- National Cancer Research Institute Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome Trial 16

 

AML 17- Working parties on leukaemia in adults and children trial in acute myeloid leukaemia or high risk myelodysplastic syndrome 17

 

MERIT- MyEloma Renal Impairment Trial

 

MRC Myeloma IX- A randomised trial comparing second generation vs third generation bisphosphonates, induction chemotherapy regimens (CVAD vs CTD, and MP vs CTDa) and thalidomide maintenance vs no maintenance therapy. There are 2 optional bortezomib-dexamethasone sub-protocols. The first for patients in the intensive pathway showing No Change (NC) or Progressive Disease (PD) after 2 cycles of randomised induction chemotherapy and secondly for patients at first relapse

 

Myeloma X Relapse (Intensive)- Myeloma X Relapse (Intensive)-a comparison of high versus low-dose alkylating agent consolidation regimens for relapsed myeloma

 

MYELOMA XI- Randomised comparisons in myeloma patients of all ages of thalidomide, lenalidomide and bortezomib combinations and maintenance lenalidomide

 

SPIRIT 2- STI571 Prospective International RandomIsed Trial 2: A phase III, prospective randomised comparison of imatinib (STI571, Glivec/Gleevec) 400mg daily versus dasatinib (Sprycel) 100mg daily in patients with newly-diagnosed chronic phase chronic myeloid leukaemia

 

  • LYMPHOMA

 

RATHL- A randomised phase III trial to assess response adapted therapy using FDG-PET imaging in patients with newly diagnosed, advanced hodgkin lymphoma

 

The role of the oncogenic E3 ligase, MDM2, in governing the function of the PIM1 and PIM2 protein ki- The role of the oncogenic E3 ligase, MDM2, in governing the function of the PIM1 and PIM2 protein kinases in B cells and lymphomas.

 

  • MELANOMA

 

AVAST-M- Adjuvant aVAStin Trial in high risk Melanoma - A randomised trial evaluating the VEGF inhibitor, bevacizumab (Avastin®),as adjuvant therapy following resection of AJCC stage IIB (T3bN0M0 & T4aN0M0), IIC (T4bN0M0) and III (TxN1-3M0) cutaneous melanoma

 

EORTC 18032- Extended schedule, escalated dose Temozolomide versus Dacarbazine in Stage IV Metastatic Melanoma: A Randomised Phase III Study of the EORTC Melanoma Group

 

  • PALLIATIVE CARE

 

Pregabalin study- Double-blind randomised controlled trial of pregabalin versus placebo in conjunction with palliative radiotherapy for malignant bone pain

 

  • SKIN

 

LIMIT-1- Effect of topical imiquimod on lentigo maligna

 

Molecular pathogenesis of non-melanoma skin cancers- Identification of critical molecular and biological events in the genesis of non-melanoma skin cancers and their modification by environment, immune status and viral infection

 

  • UPPER GI

 

BILCAP- A randomised clinical trial evaluating adjuvant chemotherapy with capecitabine compared to expectant treatment alone following surgery for biliary tract cancer

 

BOSS- Barrett’s Oesophagus two yearly Surveillance versus no Surveillance: a randomised controlled trial to estimate effectiveness and cost-effectiveness

 

SCALOP- A multi-centre randomised phase II study of induction chemotherapy followed by gemcitabine or capecitabine based chemoradiotherapy for locally advanced non-metastatic pancreatic cancer

 

SCOPE 1- A randomised phase II/III multi-centre clinical trial of definitive chemoradiation, with or without cetuximab, in carcinoma of the oesophagus